Alligator Bioscience Aktie (A2AN1Z

Aktuelle Nachrichten zu Alligator Bioscience

Weitere Nachrichten

Das berichten andere über Alligator Bioscience

BioStock: Alligator’s CEO: “We are not surprised by the positive readout”

Lund-based Alligator Bioscience continue to strengthen the case for their phase II candidate mitazalimab with 24-months data. BioStock reached out to CEO Søren Bregenholt...

BioStock: Updated data further bolsters Alligator’s mitazalimab

Lund-based Alligator Bioscience continue to strengthen the case for their phase II candidate mitazalimab. The stock jumped 67 per cent today after encouraging updated results...

BioStock: Alligators CEO: "Im confident that we will strike a deal"

Alligator Bioscience is currently conducting a rights issue aimed at advancing mitazalimab towards phase III and securing a partnership. CEO Søren Bregenholt joins BioStock’s...

BioStock: Alligator’s CEO: “We are on track to secure a partnership”

Alligator Bioscience is undertaking a restructuring and planning a rights issue of approximately SEK 280 million. This move aims to concentrate efforts on its lead drug candidate,...